Emerging drugs for pulmonary hypertension

Bibliography

• Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull NY Acad Med 1954;30:195-207
   PubMedGoogle Scholar
• Badesch DB, Champion HC, Sanchez MA, Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-66
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins IM, Beghetti M, Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54
   PubMed Web of Science ®Google Scholar
• Fell CD, Martinez FJ. The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. Chest 2007;131:641-3
   PubMed Web of Science ®Google Scholar
• Tuder RM. Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009;30:376-85
   PubMed Web of Science ®Google Scholar
• Morrell NW, Adnot S, Archer SL, Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S20-31
   PubMed Web of Science ®Google Scholar
• Hassoun PM, Mouthon L, Barbera JA, Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54:S10-19
   PubMed Web of Science ®Google Scholar
• Machado RD, Eickelberg O, Elliott CG, Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S32-42
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30
   PubMed Web of Science ®Google Scholar
• Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007;30:1103-10
   PubMed Web of Science ®Google Scholar
• Garin MC, Clark L, Chumney EC, Cost-utility of treatments for pulmonary arterial hypertension: a markov state-transition decision analysis model. Clin Drug Investig 2009;29:635-46
   PubMed Web of Science ®Google Scholar
• Rubenfire M, Lippo G, Bodini BD, Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need. Chest 2009;136:597-603
   PubMed Web of Science ®Google Scholar
• Hyduk A, Croft JB, Ayala C, Pulmonary hypertension surveillance–United States, 1980-2002. MMWR Surveill Summ 2005;54:1-28
   PubMedGoogle Scholar
• Hoeper MM, Barbera JA, Channick RN, Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54:S85-96
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94
   PubMed Web of Science ®Google Scholar
• Barst RJ, Gibbs JS, Ghofrani HA, Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S78-84
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H, Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8
   PubMed Web of Science ®Google Scholar
• Badesch DB, McGoon MD, Barst RJ, Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 2009;36:2244-9
   Google Scholar
• Simonneau G, Barst RJ, Galie N, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4
   PubMed Web of Science ®Google Scholar
• Barst RJ, Galie N, Naeije R, Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28:1195-203
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Tapson VF, Benza RL, Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005;172:1586-9
   PubMed Web of Science ®Google Scholar
• Tapson VF, Gomberg-Maitland M, McLaughlin VV, Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006;129:683-8
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N, Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
   PubMed Web of Science ®Google Scholar
• Opitz CF, Wensel R, Winkler J, Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005;26:1895-902
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Leuchte H, Halank M, Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-4
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Rubin L, Benza RL, TRIUMPH I: efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med 2008;177:A965
   Google Scholar
• Channick RN, Simonneau G, Sitbon O, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23
   PubMed Web of Science ®Google Scholar
• Galie N, Rubin L, Hoeper M, Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Sitbon O, Badesch DB, Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9
   PubMed Web of Science ®Google Scholar
• Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40
   PubMed Web of Science ®Google Scholar
• Galie N, Beghetti M, Gatzoulis MA, Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54
   PubMed Web of Science ®Google Scholar
• Degano B, Yaici A, Le Pavec J, Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009;33:92-8
   PubMed Web of Science ®Google Scholar
• Humbert M, Segal ES, Kiely DG, Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44
   PubMed Web of Science ®Google Scholar
• Prefontaine A, Calderone A, Dupuis J. Role of endothelin receptors on basal and endothelin-1-stimulated lung myofibroblast proliferation. Can J Physiol Pharmacol 2008;86:337-42
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Frost A, Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Badesch D, Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56
   PubMed Web of Science ®Google Scholar
• Benza RL, Barst RJ, Galie N, Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 2008;134:775-82
   PubMed Web of Science ®Google Scholar
• Hoeper MM. Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy? Eur Respir J 2009;34:529-30
   PubMed Web of Science ®Google Scholar
• Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 2008;29:1936-48
   PubMed Web of Science ®Google Scholar
• Galie N, Olschewski H, Oudiz RJ, Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-19
   PubMed Web of Science ®Google Scholar
• Oudiz R. Ambrisentan therapy in patients with pulmonary arterial hypertension: 2-year outcome [abstract]. Chest 2008;134:s40001
   Google Scholar
• Chung KY, Kang M, Walker JW. Contractile regulation by overexpressed ETA requires intact T tubules in adult rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2008;294:H2391-9
   PubMed Web of Science ®Google Scholar
• Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343:1342
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A, Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Gilbert C, Collings L, Brown MC. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008;133:183-9
   PubMed Web of Science ®Google Scholar
• Galie N, Brundage BH, Ghofrani HA, Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903
   PubMed Web of Science ®Google Scholar
• Montani D, Chaumais MC, Savale L, Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009 [Epub ahead of print]
   Google Scholar
• Wrishko RE, Dingemanse J, Yu A, Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008;48:610-18
   PubMed Web of Science ®Google Scholar
• Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008;64:43-50
   PubMed Web of Science ®Google Scholar
• Simonneau G, Rubin LJ, Galie N, Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-30
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Negro L, A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
   PubMed Web of Science ®Google Scholar
• Souza R, Humbert M, Sztrymf B, Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008;31:343-8
   PubMed Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Peacock AJ, Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7
   PubMed Web of Science ®Google Scholar
• Du L, Sullivan CC, Chu D, Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003;348:500-9
   PubMed Web of Science ®Google Scholar
• Bogaard HJ, Abe K, Vonk NA, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009;135:794-804
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V, Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25
   PubMed Web of Science ®Google Scholar
• Kunieda T, Nakanishi N, Matsubara H, Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. Int Heart J 2009;50:513-29
   PubMed Web of Science ®Google Scholar
• White RJ. Update on the development of oral prostacyclin analogs for the treatment of PAH. Adv Pulm Hypertens 2009;8:32-6
   Google Scholar
• Kuwano K, Hashino A, Noda K, A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008;326:691-9
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Asaki T, 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007;322:1181-8
   PubMed Web of Science ®Google Scholar
• Iglarz M, Binkert C, Morrison K, Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-45
   PubMed Web of Science ®Google Scholar
• Sommer F. Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor. Expert Opin Drug Metab Toxicol 2005;1:295-301
   PubMedGoogle Scholar
• Jing ZC, Jiang X, Wu BX, Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart 2009;95:1531-6
   PubMed Web of Science ®Google Scholar
• Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009;191:277-308
   PubMedGoogle Scholar
• Grimminger F, Weimann G, Frey R, First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33:785-92
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Hoeper M, Hoeffken G, Riociguat Dose Titration in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or Pulmonary Arterial Hypertension (PAH) [abstract]. Am J Respir Crit Care Med 2009;179:A3337
   Google Scholar
• Kalinowski L, Dobrucki IT, Malinski T. Cicletanine stimulates nitric oxide release and scavenges superoxide in endothelial cells. J Cardiovasc Pharmacol 2001;37:713-24
   PubMed Web of Science ®Google Scholar
• Saadjian A, Philip-Joet F, Paganelli F, Long-term effects of cicletanine on secondary pulmonary hypertension. J Cardiovasc Pharmacol 1998;31:364-71
   PubMed Web of Science ®Google Scholar
• Waxman AB, Lawler L, Cornett G. Cicletanine for the treatment of pulmonary arterial hypertension. Arch Intern Med 2008;168:2164-6
   PubMed Web of Science ®Google Scholar
• Moens AL, Kass DA. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 2006;26:2439-44
   PubMed Web of Science ®Google Scholar
• Khoo JP, Zhao L, Alp NJ, Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation 2005;111:2126-33
   PubMed Web of Science ®Google Scholar
• Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008;7:156-67
   PubMed Web of Science ®Google Scholar
• Schwedhelm E, Maas R, Freese R, Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol 2008;65:51-9
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan M, Barr FE, Summar ML, L-Citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets. Am J Physiol Lung Cell Mol Physiol 2009;297:L506-11
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-13
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Morrell NW, Hoeper M, Imatinib in patients with severe Pulmonary Artery Hypertension (PAH) refractory to standard therapy [abstract]. Am J Respir Crit Care Med 2009;179:A1044
   Google Scholar
• Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008;118:84-95
   PubMed Web of Science ®Google Scholar
• Klein M, Schermuly RT, Ellinghaus P, Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008;118:2081-90
   PubMed Web of Science ®Google Scholar
• Oka M, Fagan KA, Jones PL, McMurtry IF. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008;155:444-54
   PubMed Web of Science ®Google Scholar
• Ishikura K, Yamada N, Ito M, Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006;70:174-8
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Matoba T, Ito A, Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91:391-2
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Shibuya M, Satoh S, A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 2007;68:126-31
   PubMed Web of Science ®Google Scholar
• Olsson KM, Hoeper MM. Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. Drug Discov Today 2009;14:284-90
   PubMed Web of Science ®Google Scholar
• Guignabert C, Raffestin B, Benferhat R, Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005;111:2812-19
   PubMed Web of Science ®Google Scholar
• Shah SJ, Gomberg-Maitland M, Thenappan T, Rich S. Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest 2009;136:694-700
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Weir EK. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci 2001;321:292-9
   PubMed Web of Science ®Google Scholar
• Chambers CD, Hernandez-Diaz S, Van Marter LJ, Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87
   PubMed Web of Science ®Google Scholar
• Rhodes CJ, Davidson A, Gibbs JS, Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009;121:69-88
   PubMed Web of Science ®Google Scholar
• Zhao L, Sebkhi A, Ali O, Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 2009;34:948-57
   PubMed Web of Science ®Google Scholar
• Dickson L, Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol Ther 2009;121:294-316
   PubMed Web of Science ®Google Scholar
• Said SI, Hamidi SA, Dickman KG, Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007;115:1260-8
   PubMed Web of Science ®Google Scholar
• Petkov V, Mosgoeller W, Ziesche R, Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-46
   PubMed Web of Science ®Google Scholar
• Archer SL, Gomberg-Maitland M, Maitland ML, Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 2008;294:H570-8
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Bonnet S, Wu X, Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004;95:830-40
   PubMed Web of Science ®Google Scholar
• Zhao YD, Courtman DW, Deng Y, Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96:442-50
   PubMed Web of Science ®Google Scholar
• Toshner M, Voswinckel R, Southwood M, Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med 2009;180:780-7
   PubMed Web of Science ®Google Scholar
• Wang XX, Zhang FR, Shang YP, Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007;49:1566-71
   PubMed Web of Science ®Google Scholar
• Dickstein K, De Voogd HJ, Miric MP, Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 2004;94:237-9
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 2008;118:1195-201
   PubMed Web of Science ®Google Scholar